NovaBridge Biosciences (FRA:0VY) Interest Expense: €0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0VY NovaBridge Biosciences FRA:0VY
30 GF Score
Price €1.57
! 3 Warning Signs
View Full Analysis

What is NovaBridge Biosciences Interest Expense?

NovaBridge Biosciences FRA:0VY +1.29% 30 Interest Expense is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:0VY with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. NovaBridge Biosciences's interest expense for the three months ended in Dec. 2025 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. NovaBridge Biosciences's Operating Income for the three months ended in Dec. 2025 was € -62.26 Mil. NovaBridge Biosciences's Interest Expense for the three months ended in Dec. 2025 was € 0.00 Mil. GuruFocus does not calculate NovaBridge Biosciences's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NovaBridge Biosciences  (FRA:0VY) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NovaBridge Biosciences's Interest Expense for the three months ended in Dec. 2025 was €0.00 Mil. Its Operating Income for the three months ended in Dec. 2025 was €-62.26 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2025 was €1.86 Mil.

NovaBridge Biosciences's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

GuruFocus does not calculate NovaBridge Biosciences's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. NovaBridge Biosciences has enough cash to cover all of its debt. Its financial situation is stable.

NovaBridge Biosciences Interest Expense Historical Data

* Premium members only.

The historical data trend for NovaBridge Biosciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovaBridge Biosciences Interest Expense Chart

NovaBridge Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only 0.00 -0.00 -0.09 0.00 0.00

NovaBridge Biosciences Quarterly Data
Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:0VY
30GF Score
NovaBridge Biosciences FRA:0VY
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovaBridge Biosciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €0.00 Mil mean?
NovaBridge Biosciences (FRA:0VY) has a Interest Expense of €0.00 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on NovaBridge Biosciences and its competitors.
Is NovaBridge Biosciences' Interest Expense too high?
NovaBridge Biosciences' current Interest Expense is €0.00 Mil. Overall, NovaBridge Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does NovaBridge Biosciences' Interest Expense compare to HUMA and DTIL?
NovaBridge Biosciences' Interest Expense of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on NovaBridge Biosciences and its competitors. NovaBridge Biosciences's current Interest Expense is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovaBridge Biosciences stock overvalued right now?
NovaBridge Biosciences (FRA:0VY) has a current Interest Expense of €0.00 Mil. The current Interest Expense is €0.00 Mil. NovaBridge Biosciences' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For NovaBridge Biosciences (FRA:0VY), the current Interest Expense is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NovaBridge Biosciences Business Description

Other Exchanges NBP:USA
Address 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
30GF Score

Get the complete analysis for FRA:0VY

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.57
Price